Descrizione del progetto
Il microbioma intestinale per lottare contro l’infezione da HIV
Nonostante il microbioma sia stato oggetto di intense ricerche negli ultimi decenni, pochissime pubblicazioni hanno affrontato il suo potenziale ruolo nell’HIV/AIDS e molte di queste si sono concentrate sul microbioma genitale. Sempre più prove sostengono il ruolo del microbioma intestinale in disturbi del sistema immunitario, infiammazione cronica e invecchiamento accelerato, tutti segni distintivi dell’infezione da HIV-1. Il progetto MISTRAL, finanziato dall’UE, sta esplorando il microbiota intestinale in relazione all’HIV-1, cercando biomarcatori microbiomici a supporto dello sviluppo di interventi che mitighino l’infezione e rafforzino la risposta a vaccini e terapie. Inoltre, la creazione di una banca dati pubblicamente accessibile contribuirà a controllo e stratificazione nei degenti. Uno strumento basato su cloud faciliterà anche l’interpretazione del microbioma per finalità di ricerca e cliniche.
Obiettivo
The HIV/AIDS pandemic continues to be one of the major health challenges ever faced by mankind. Far from being resolved, HIV is soaring in Eastern Europe (60% increase in new infections and 27% increase in deaths since 2010) and other regions of the world despite increasing access to antiretroviral treatment. There is emerging evidence that the human microbiome impacts some of the most important clinical aspects of HIV-1 infection, including immune disorders, chronic inflammation and accelerated aging. Work in other viral diseases and cancer immunotherapy suggest a critical role of the human microbiome also in the outcome of immune therapeutic interventions in HIV-1 infection. The MISTRAL project brings together a team of world-class HIV and microbiome researchers and SMEs with ideal complementary knowledge and expertise. This team will work to discover and validate novel gut microbiome biomarkers to inform rationally-designed, mechanistically-driven interventions on the gut microbiome to mitigate HIV-1 acquisition, systemic inflammation, chronic clinical complications, antimicrobial drug resistance, and boost the efficacy of HIV cure immunotherapies. Integrated and curated large microbiome and host datasets generated during the execution of the project will be made public through a freely accessible, specifically-dedicated web-based repository. Biomarker discoveries will be incorporated into a cloud-based software tool that will automate microbiome analyses and interpretations, thus streamlining patient stratification for clinical and research purposes. If successful, MISTRAL will benefit millions of human beings living with, or at risk of acquiring HIV-1 infection, and will produce novel concepts and technical innovations applicable to other human diseases. By doing that, MISTRAL will help to unlock the full clinical potential of the human microbiome to stratify patient outcomes and will irreversibly bring microbiome science closer to clinical practice.
Campo scientifico
Parole chiave
Programma(i)
Invito a presentare proposte
Vedi altri progetti per questo bandoBando secondario
H2020-SC1-2019-Two-Stage-RTD
Meccanismo di finanziamento
RIA - Research and Innovation actionCoordinatore
08916 Barcelona
Spagna